This site is intended for healthcare professionals

FDA accepts for priority review the BLA for V114, investigational 15-valent pneumococcal conjugate vaccine, for use in adults 18 years of age and older. - Merck Inc.

Read time: 1 mins
Last updated:14th Jan 2021
Published:14th Jan 2021
Condition: Pneumococcal Disease
Type: drug
Register for free exclusive healthcare eLearning resources

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest